AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 221 min read

OptimizeRx Corp. And The Trade Desk Bring Net New Authenticated HCP Reach To The Trade Desk Through OpenPath

OptimizeRx Corp. integrated its authenticated point-of-care inventory with The Trade Desk's OpenPath, enabling advertisers to access its network of 400+ EHR systems and 800,000 verified HCPs. The move expands healthcare inventory for life sciences advertisers and is expected to launch in Q4 2026.

Original reporting
marketscreener.com
Published Sep 22, 2026, 3:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 4:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$OPRX
Relevance
4/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Low
01

Why it matters

The integration enables advertisers to access 800,000 verified HCPs through OpenPath, potentially increasing demand for health‑tech ad inventory.

02

Market read

First disclosure of a new supply‑path partnership that could modestly broaden ad inventory for life‑sciences marketers.

03

What to watch

Potential regulatory scrutiny of health data usage and integration complexity could delay impact.

Relevance 4/10Novelty 4/10Timing: integration rollout in Q4 2026

Background

OptimizeRx provides point‑of‑care inventory via EHR and e‑prescribe systems; The Trade Desk offers a DSP for programmatic buying.

Market effects

Sector

Expands programmatic HCP inventory for life‑sciences advertisers, modest impact on health‑tech ad spend.

Regional

U.S. digital advertising market; limited immediate regional effect.

Global

Relevant to global pharma advertising ecosystem but low overall market relevance.

Counterpoint

What could challenge this read

The partnership may not translate into significant revenue without broader adoption by advertisers.

Key entities

  • Company
    OptimizeRx Corp.

    Provider of authenticated point‑of‑care inventory for health‑care advertisers.

  • Company
    The Trade Desk

    Programmatic demand‑side platform facilitating digital ad purchases.

Read at source← All news

Related articles

AUG 12
$OPRXMed

OptimizeRx Corp (OPRX): Results of Operations and Financial Condition

OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million

SEC EDGAR 8-K4 min
SEP 22
$AMGNMedAI 8/10

AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’

Amgen (AMGN) shares rose 4% after reporting positive late-stage trial results for dazodalibep in treating systemic Sjögren’s disease, a condition with no approved therapy. The trial showed significant improvement in disease intensity. Citi noted positive results but awaits more details, maintaining a Neutral rating and $405 price target. AMGN is up 25% year-to-date.

stocktwits.com2 min
SEP 22
$VRTXMedAI 8/10

Vertex Pharmaceuticals Stock Gains On Kidney Drug Data - Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (VRTX) reported positive Phase 2b trial results for inaxaplin in treating APOL1-mediated kidney disease. The drug showed significant proteinuria reductions in two patient groups, with a favorable safety profile. Vertex expects interim Phase 2/3 trial results in early 2027, which could support U.S. approval. William Blair reiterated an Outperform rating, citing potential growth. VRTX shares rose 2.04% to $521.14.

benzinga.com4 min
SEP 22
$VRTXMedAI 8/10

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder

Vertex Pharmaceuticals (VRTX) shares rose 3% after reporting positive trial results for inaxaplin in APOL1-mediated kidney disease (AMKD). The drug reduced protein leakage in urine by 42.7% for albumin and 44.7% for total protein in patients with modest proteinuria. Rival Maze Therapeutics (MAZE) shares jumped 25% on the read-through. Truist called the data a validation of APOL1 inhibition, estimating a market of over 100,000 patients and potential blockbuster sales for Maze's MZE829.

newsable.asianetnews.com2 min